News Search Results
Aug 21, 2026, 03:24 ET 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
launch: 3SBio has established a robust pipeline of five products currently under NDA review, covering therapeutic areas such as atopic dermatitis, ophthalmology, breast cancer, and weight management. Among them, NDAs have been accepted for 611 (anti-IL-4Rα mAb) for moderate-to-severe atopic
More news about: 3SBio Inc.
Aug 20, 2026, 13:10 ET ZEISS Helps Manufacturers Find Certainty at IMTS 2026
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Aug 20, 2026, 08:00 ET Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
said Henric Bjarke, Chief Executive Officer, Tenpoint. "Lupin's strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma's longstanding presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI™ to
More news about: Lupin Limited
Aug 20, 2026, 07:30 ET Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
Aug 20, 2026, 05:00 ET Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
said Henric Bjarke, Chief Executive Officer, Tenpoint. "Lupin's strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma's longstanding presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI™ to
More news about: Lupin Limited
Aug 19, 2026, 09:00 ET ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
the increasing adoption of digital ophthalmic tools in the U.S., has firmly positioned ZEISS at the forefront of empowering ophthalmologists. As ophthalmology continues to adopt connected technologies, clinicians need solutions that fit seamlessly into how their practice operates," says Federico Villegas,
More news about: Carl Zeiss Meditec AG
Aug 19, 2026, 09:00 ET ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
the increasing adoption of digital ophthalmic tools in the U.S., has firmly positioned ZEISS at the forefront of empowering ophthalmologists. As ophthalmology continues to adopt connected technologies, clinicians need solutions that fit seamlessly into how their practice operates," says Federico Villegas,
More news about: Carl Zeiss Meditec AG
Aug 18, 2026, 15:44 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. For more information, visit: Piramal
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:36 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. For more information, visit: Piramal
More news about: Piramal Pharma Solutions
Aug 18, 2026, 11:00 ET Restoring a Missing Slice of Sunshine to Indoor Light May Help Prevent Myopia
Richard Lang, PhD, director of research in the Division of Ophthalmology at Cincinnati Children's. "So, if indigo light can suppress myopia in these tests, then it should also be quite effective in humans."What
More news about: Cincinnati Children's Hospital Medical Center
Aug 18, 2026, 09:00 ET Century Health and GI Partners of Illinois Partner to Advance Real-World Evidence in IBD and MASH
research-grade datasets with accuracy validated against clinical expert judgment. Spanning therapeutic areas including neurology, immunology, and ophthalmology, the company's proprietary specialty provider network covers more than 200 sites and 600,000 longitudinal patient records across 12 disease areas.
More news about: Century Health
Aug 18, 2026, 09:00 ET PM360 Announces 2026 Trailblazer Award Finalists
CorporationNephrology/Urology: Samantha Meyers, Sr. Director of Digital Strategy, Bayer PharmaceuticalsOphthalmology/Optometry: Matt Gibson, Senior Director of Marketing, Interventional Dry Eye, Sight SciencesOphthalmology/Optometry: Lisa Jensen, Senior Director, Global Marketing - Corneal Health, Glaukos
More news about: PM360
Aug 13, 2026, 09:00 ET Intermountain Health Brings Perimeter's Claire™ to the Operating Room, a Landmark in Breast Cancer Surgery Using AI
platform, which was cleared by the FDA for general tissue imaging and uses optical coherence tomography, a light-based imaging technology used in ophthalmology and cardiology. The OCT provides real-time, cellular-level visualization of tissue, while the AI available in Claire sifts through the images generated
More news about: Perimeter Medical Imaging AI Inc.
Aug 13, 2026, 07:05 ET SamaCare Named 2026 Prix Galien USA Finalist for Best Digital Health Solution
for the providers and patients navigating it every day."SamaCare supports provider-administered specialty medications across oncology, ophthalmology/retina, neurology, rheumatology, immunology, gastroenterology, rare disease, ambulatory infusion, and other specialty care settings. Its intelligent
More news about: SamaCare
Aug 12, 2026, 09:04 ET AMSURG Welcomes Louisiana-Based Capital Surgery Center to Its National Network
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. Guided by its core values — Care Deeply, Champion Excellence, Cultivate Integrity and Celebrate Teamwork — AMSURG is committed
More news about: AMSURG Corporation
Aug 11, 2026, 17:31 ET New MedStar Health Urgent Care Location to Provide Expanded Services for Gallaudet University Students
Telehealth consultations, when needed, with cardiology, emergency medicine, ENT (ear, nose, and throat), ophthalmology, orthopedics, pediatrics and spine specialistsLanguage interpretation, including ASLGallaudet University students will now
More news about: MedStar Health
Aug 11, 2026, 06:30 ET Keenova Reports Second Quarter 2026 Financial Results
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
isoform (PKM2) modulator. PKM2 modulation offers a potential new paradigm for treating large, underserved, and high-value indications in neurology, ophthalmology, and immunology and exhibits robust beneficial effects across a spectrum of preclinical models of Alzheimer's, and multiple sclerosis, specifically
More news about: Biohaven Ltd.
Aug 06, 2026, 16:05 ET Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
forms.The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.Conference Call InformationThe
More news about: Amphastar Pharmaceuticals, Inc.
Aug 06, 2026, 08:30 ET Roche expands cyclospora testing portfolio to support U.S. public health response
Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals
More news about: ROCHE DIAGNOSTICS CORPORATION
Aug 06, 2026, 02:00 ET Norlase Expands European Footprint with Direct Commercial Operations in Germany
technology as we continue to grow."Mr. Dalhoff brings more than 25 years of experience in technical sales and clinical application support across ophthalmology and optical technology, including prior roles at Ellex Deutschland GmbH, where he supported the clinical use of therapeutic laser technologies such
More news about: Norlase
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&D code: TAK-928),
More news about: Innovent Biologics
Aug 05, 2026, 07:00 ET InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.Forward-Looking
More news about: InMode Ltd.
Aug 05, 2026, 05:34 ET Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
leading global pharmaceutical companies. The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities
More news about: Everest Medicines
Aug 04, 2026, 10:00 ET Q2BI Expands Asia-Pacific Footprint with New Offices in Taipei, Kuala Lumpur, and Melbourne
of therapeutic areas, including oncology, hematology, central nervous system disorders, immunology, infectious diseases, cardiovascular disease, ophthalmology, rare diseases, and endocrine and metabolic disorders.Q2BI has also made significant investments in artificial intelligence and data science.
More news about: Q-Square Business Intelligence (Q2BI)